Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Felices

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Blood|August 2, 2022
Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemiaFrank Cichocki, Jodie P Goodridge, Ryan Bjordahl, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 10, 2019
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer ImmunotherapyEmily J Pomeroy, John T Hunzeker, Mitchell G Kluesner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2023
Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine ProductionJames D Dahlvang, Jenna K Dick, Jules A Sangala, et al.
Device|April 6, 2026
A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancerAoibhin M Sheedy, Mihir Shetty, Anna Weis, et al.
Neuro-Oncology|July 11, 2026
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engagerJian-Fang Ning, Zachary B Davis, Qudsia Zeb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell TransplantationZachary B Davis, Sarah A Cooley, Frank Cichocki, et al.
Science Translational Medicine|November 5, 2020
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapyFrank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, et al.
Blood|August 26, 2025
Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiencyJacob Myers, Rih-Sheng Huang, Shee Kwan Phung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Science Advances|October 30, 2024
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environmentsPhilippa R Kennedy, Upasana Sunil Arvindam, Shee Kwan Phung, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Blood|August 2, 2022
Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemiaFrank Cichocki, Jodie P Goodridge, Ryan Bjordahl, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 10, 2019
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer ImmunotherapyEmily J Pomeroy, John T Hunzeker, Mitchell G Kluesner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2023
Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine ProductionJames D Dahlvang, Jenna K Dick, Jules A Sangala, et al.
Device|April 6, 2026
A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancerAoibhin M Sheedy, Mihir Shetty, Anna Weis, et al.
Neuro-Oncology|July 11, 2026
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engagerJian-Fang Ning, Zachary B Davis, Qudsia Zeb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell TransplantationZachary B Davis, Sarah A Cooley, Frank Cichocki, et al.
Science Translational Medicine|November 5, 2020
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapyFrank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, et al.
Blood|August 26, 2025
Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiencyJacob Myers, Rih-Sheng Huang, Shee Kwan Phung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Science Advances|October 30, 2024
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environmentsPhilippa R Kennedy, Upasana Sunil Arvindam, Shee Kwan Phung, et al.
Pageof 8